Clinical Trials
25 trialsNCT03093116 2026-05-27
TRIDENT-1
Turning Point Therapeutics, Inc.
Phase 1/2 Recruiting
NCT07416188 2026-05-27
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT07377487 2026-05-22
INDIGO
Boston Scientific Corporation
Phase NA Recruiting
NCT03911388 2026-05-15
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05297734 2026-04-30
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Stanford University
Phase NA Recruiting
NCT07075185 2026-04-24
inMMyCAR
Kelonia Therapeutics, Inc.
Phase 1 Recruiting
NCT07216443 2026-04-15
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Orca Biosystems, Inc.
Phase 2 Recruiting
NCT06001788 2026-04-14
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
Phase 1 Recruiting
NCT05722886 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT05768178 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT05770037 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT05770102 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT05770544 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT06988475 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT06463665 2025-09-26
VIRO-25
Genelux Corporation
Phase 2 Recruiting
NCT04572451 2025-08-01
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
University of Pittsburgh
Phase 1 Recruiting
NCT05963217 2025-07-02
Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL
University Health Network, Toronto
Phase 1 Recruiting
NCT04104776 2025-05-15
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Novartis
Phase 1/2 Recruiting
NCT04593407 2025-03-13
intERsection
Hospital Universitario 12 de Octubre
Phase NA Recruiting
NCT06644443 2024-10-16
BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma
Shenzhen University General Hospital
Phase 1/2 Recruiting
NCT04097067 2024-08-27
ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma
University Hospital Muenster
Phase NA Recruiting
NCT06271252 2024-08-02
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
OriCell Therapeutics Co., Ltd.
Phase 1 Recruiting
NCT05440240 2023-05-17
Percutaneous Needle Fasciotomy +/- Corticosteroid Injection for Dupuytren's Contracture
Regionshospitalet Silkeborg
Phase 4 Recruiting
NCT05252078 2022-12-16
ALTER-E005
Jiangxi Provincial Cancer Hospital
Phase 2 Recruiting
NCT03351842 2017-12-19
Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Recruiting